The direct offering is a significant financial move for CRISPR Therapeutics, indicating strong investor confidence led by EcoR1 Capital and SR One. The funds are earmarked for critical areas such as oncology, cardiovascular, diabetes, auto-immune, and gene writing programs, which are essential for the company's growth and innovation. The enhanced cash position over $2.1 billion provides a solid financial foundation, likely leading to a positive short-term impact on the stock price due to increased investor confidence and the potential for accelerated development and expansion of its programs.